Global Patent Index - EP 1925319 A4

EP 1925319 A4 20100106 - PHARMACEUTICAL COMPOSITIONS CONTAINING SC(FV)2

Title (en)

PHARMACEUTICAL COMPOSITIONS CONTAINING SC(FV)2

Title (de)

SC(FV)2 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Title (fr)

COMPOSITIONS PHARMACEUTIQUES CONTENANT DU SC(FV)2

Publication

EP 1925319 A4 20100106 (EN)

Application

EP 06766512 A 20060609

Priority

  • JP 2006311600 W 20060609
  • JP 2005171375 A 20050610
  • JP 2006306800 W 20060331

Abstract (en)

[origin: EP1925319A1] The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.

IPC 8 full level

A61K 39/395 (2006.01); A61K 9/19 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2006.01); A61K 47/18 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/46 (2006.01); A61P 43/00 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01)

CPC (source: EP US)

A61K 9/0019 (2013.01 - EP); A61K 9/19 (2013.01 - EP); A61K 39/39591 (2013.01 - EP); A61K 47/02 (2013.01 - EP); A61K 47/183 (2013.01 - EP US); A61K 47/26 (2013.01 - EP US); A61P 43/00 (2017.12 - EP); G01N 33/6854 (2013.01 - EP US); C07K 2317/622 (2013.01 - EP); G01N 2500/04 (2013.01 - EP)

Citation (search report)

  • [XY] MACK M ET AL: "A SMALL BISPECIFIC ANTIBODY CONSTRUCT EXPRESSED AS A FUNCTIONAL SINGLE-CHAIN MOLECULE WITH HIGH TUMOR CELL CYTOTOXICITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 92, no. 15, 18 July 1995 (1995-07-18), pages 7021 - 7025, XP000566333, ISSN: 0027-8424
  • [Y] MOORE J M R ET AL: "Kinetics and Thermodynamics of Dimer Formation and Dissociation for a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 38, no. 42, 28 September 1999 (1999-09-28), pages 13960 - 13967, XP007901441, ISSN: 0006-2960
  • [A] ZHU ET AL: "REMODELLING DOMAIN INTERFACES TO ENHANCE HETERODIMER FORMATION", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 6, no. 4, 1 April 1997 (1997-04-01), pages 781 - 788, XP002084764, ISSN: 0961-8368
  • [A] ORITA T ET AL: "A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 105, no. 2, 15 January 2005 (2005-01-15), pages 562 - 566, XP002377285, ISSN: 0006-4971
  • [A] KORN T ET AL: "Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv", JOURNAL OF GENE MEDICINE, WILEY, US, vol. 6, no. 6, 1 January 2004 (2004-01-01), pages 642 - 651, XP003005521, ISSN: 1099-498X
  • [A] KONTERMANN ROLAND E: "Recombinant bispecific antibodies for cancer therapy", ACTA PHARMACOLOGICA SINICA, NATURE PUBLISHING GROUP, US; CN, vol. 26, no. 1, 1 January 2005 (2005-01-01), pages 1 - 9, XP002426874, ISSN: 1671-4083
  • See references of WO 2006132352A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

EP 1925319 A1 20080528; EP 1925319 A4 20100106; EP 1925319 B1 20180307; AU 2006256030 A1 20061214; AU 2006256030 B2 20120621; CA 2611726 A1 20061214; CA 2611726 C 20170711; WO 2006132352 A1 20061214

DOCDB simple family (application)

EP 06766512 A 20060609; AU 2006256030 A 20060609; CA 2611726 A 20060609; JP 2006311600 W 20060609